Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. - Test2 - elhamkhani - TriplyDB

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

http://www.wikidata.org/entity/Q34526404

about

Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies What Are the Most Powerful Immunogen Design Vaccine Strategies?Survivors Remorse: antibody-mediated protection against HIV-1.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1.HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.Progress toward active or passive HIV-1 vaccination.Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies Native-like Env trimers as a platform for HIV-1 vaccine design.Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution.An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.Use of broadly neutralizing antibodies for HIV-1 prevention.Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies.Approaches to the induction of HIV broadly neutralizing antibodies.Evolution of B cell analysis and Env trimer redesign.Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development.The HIV-1 envelope glycoprotein structure: nailing down a moving target.Identification and specificity of broadly neutralizing antibodies against HIV How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer.Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer.HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism.A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.Conformational Heterogeneity of the HIV Envelope Glycan Shield.Env-Specific Antibodies in Chronic Infection versus in Vaccination.Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor.HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

P2860

Q27654848-57CCAD41-D40C-4092-BEC2-95879B5A974E Q28066335-6EA9D948-F280-4404-9C95-C662923D5789 Q28729792-D42C034A-667F-4FDA-9AC0-A08E7158AE47 Q30238730-C847116A-15E4-4779-BC44-99CE776C53D0 Q30490942-6ABF67F0-D924-49CA-AAD6-6AF9943B0185 Q34550046-F5DF9DD1-ED42-45B4-A0C3-D90878A56AFD Q36239578-E610DA0C-1D86-4B4E-80D1-5C2BA6202155 Q36246403-982B2F0B-0898-4F88-8B0A-E60C0F60C599 Q36263513-E4656A69-DC81-40A7-A1D9-E7B9053CA2D6 Q37293480-9E5A8B32-F349-4A0D-8E39-03B05646BFFC Q37549777-43B5DDE3-C803-4284-A353-6E824CE5A2F3 Q37584635-5E3AD1B2-D9E4-4C36-B85D-7EBCDE643FDC Q37621530-A9357D38-4AEA-4D55-B2DF-BF6BD30E34A8 Q37633417-5BE27476-11EF-43B5-8745-2C873008C6F6 Q37634061-78588561-1D27-4A3B-BE32-17A299B8647C Q37703084-88578AD0-B65F-4224-9770-68AB5CC71F93 Q37728775-E699D026-CC41-4892-93D6-2157C0CF1718 Q38764543-323E1333-5DBD-418D-9144-7D9AC589F082 Q38774504-E2F9B6CD-8ABE-47DC-88F5-69F5F87F1AC1 Q38862338-37165368-87CE-4CB8-B816-711BEF031A4D Q38936867-5A2F5AF5-9D2B-4E6F-A069-DB51BABBA45D Q38992740-74A70F97-6AB8-4D19-95BB-43C8A3C9C9CE Q39108751-9BB10580-F560-4981-9557-BFC9666CF425 Q39108789-9EE2475D-21D6-43F6-A6AA-5570FF50E370 Q39108796-83617D47-2E68-43D2-9C12-A600CAE0B77F Q39250593-4BF20CFB-A595-4323-91ED-71C3968635E1 Q39365785-409042B8-3E08-4980-BE63-F86D6B39EDB3 Q40056179-46BEE52B-6D61-4C77-A6E6-282A79E79766 Q40061438-E9C65C6B-399C-4578-996C-4294001E9E1A Q40083207-329D1E0F-C565-4E53-8BE4-9177CA8E1356 Q40173474-DA8964BD-F6D2-4688-B25E-424E9ECC0CF3 Q40198060-ACBBE619-0C73-49E2-91EC-F23FEF3AAE8E Q40325417-2FF4B3B3-DDBC-4D70-8F26-F35D282F912A Q40449984-24549DE5-F12B-49E5-8053-38149C61B66B Q40606158-61CA5C5C-652A-40C2-9D87-14E5014046EE Q40985221-63DFDC59-FD06-4C09-B585-C4EF355BD23C Q41475637-8E5086FC-CACD-43F3-A0FB-2E33A563C99E Q42362648-2F3E5907-DBAE-400B-88C0-83C17B4B64CE Q46454115-B4B8FB44-4696-47B3-B826-796BCD16218B Q47110966-02DD5D22-7F5C-4EDC-992D-1F2D2D7A506A

P2860

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

http://www.wikidata.org/entity/Q34526404

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@ast

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@en

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@nl

type

label

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@ast

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@en

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@nl

prefLabel

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@ast

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@en

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@nl

P1433

Q34526404-230201E7-BD5E-471A-9449-CA250308EF83

P1476

Q34526404-D7398FCB-CC31-4933-A5F7-7B2F43258153

P2093

Q34526404-00D28F22-1FE8-45E4-9845-484868B1218E

Q34526404-0148E43F-E2BA-46F0-A4FF-F6BF4CC5DC1A

Q34526404-112855D4-64A8-4CD5-9BEE-C3237E4D2649

Q34526404-12E76741-34DB-43CF-A38D-912AD1E6CD75

Q34526404-13967858-A494-42D5-97E6-2AADE07D047A

Q34526404-15BC2BC6-3A39-438E-9C55-9FC7B76170F9

Q34526404-1D2235B4-7E06-4863-A7D0-CA46CD35CB28

Q34526404-26AED10A-6A1C-4A47-9E96-D12403CFB0D0

Q34526404-2D763B63-2B72-4E98-8750-0AE3C1E9892A

Q34526404-3F543B17-B950-4482-9C2F-B45E3DE5A2D6

P2860

Q34526404-056576CA-A090-4101-813A-1227976452A8

Q34526404-1B767D28-9073-4AFB-AAD8-5B10D420855D

Q34526404-1EEA8DF8-FABE-4C7F-9B9A-BC66003B493A

Q34526404-1F6FA970-4082-461E-9ABE-238980ED5D11

Q34526404-228BF557-8348-4735-8151-B9C6C84CD275

Q34526404-24E7932F-7D7F-42F2-BBD5-0D15B92818CD

Q34526404-290F104C-76C8-439C-A064-3427782C88B2

Q34526404-2B8B7857-2601-4BAA-B8CB-389F5E51C65F

Q34526404-2C57B544-51A5-4CF2-899D-04EC15A3F13B

Q34526404-3C807E39-A7C7-41FD-A3F4-B9B086CCC76D

P304

Q34526404-C76A6565-F19C-441E-B76F-3783EFBAFAEB

P31

Q34526404-AF1D3437-FBC1-4D8C-82BF-159DA08ECFB8

P356

Q34526404-6CD45E22-A758-4B2F-8C00-74638875B870

P407

Q34526404-6BEAB040-DA5C-434B-A4B0-FE3115BBDF35

P433

Q34526404-141A1170-A307-4A6D-B49F-1F02C8C534D8

P478

Q34526404-77DC500D-9781-436F-8C42-8B230FAC65A5

P50

Q34526404-4611D174-1F21-49CC-86AC-BD27ADC5AB19

Q34526404-53B2ACA0-FE8F-4F68-A50A-E0705BBB959F

Q34526404-54101270-7083-4A9D-B97A-783C84C731D9

Q34526404-6D75E725-996B-4879-911C-486630D46F2E

Q34526404-A4DA53C6-5A04-48FD-BFE3-9A76AFDAF8D9

Q34526404-ACDCB700-B4CA-4249-A0DA-D3E7DCA6952B

P577

Q34526404-0F273C61-E050-450D-A767-F8C5123DC626

P698

Q34526404-EA7E1CF2-7023-43F1-B44C-0BBBCCEE266A

P921

Q34526404-B1CF4A20-6BDE-4193-865E-8BDBC2C1F0E7

P932

Q34526404-AD169D96-3307-40EF-B10A-192420C9C213

P356

SCIENCE.AAE0474

P1433

P1476

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

@en

P2093

Aliaksandr Druz

http://www.w3.org/2001/XMLSchema#string

Andrew B Ward

http://www.w3.org/2001/XMLSchema#string

Chang W Choi

http://www.w3.org/2001/XMLSchema#string

Dennis R Burton

http://www.w3.org/2001/XMLSchema#string

Evan M Cale

http://www.w3.org/2001/XMLSchema#string

Gabriel Ozorowski

http://www.w3.org/2001/XMLSchema#string

Gwo-Yu Chuang

http://www.w3.org/2001/XMLSchema#string

Ivelin S Georgiev

http://www.w3.org/2001/XMLSchema#string

Jinghe Huang

http://www.w3.org/2001/XMLSchema#string

Justin D Taft

http://www.w3.org/2001/XMLSchema#string

P2860

Viral membrane fusion

Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env

Molecular architecture of native HIV-1 gp120 trimers

Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16

Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer

Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

Phasercrystallographic software

The structural biology of type I viral membrane fusion

P304

828-833

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.AAE0474

http://www.w3.org/2001/XMLSchema#string

P407

P433

6287

http://www.w3.org/2001/XMLSchema#string

P478

352

http://www.w3.org/2001/XMLSchema#string

P50

Scott C Blanchard

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27174988

http://www.w3.org/2001/XMLSchema#string

P921

P932

4917739

http://www.w3.org/2001/XMLSchema#string